Akero Therapeutics: A Promising Solution For NASH Patients And Investors [Seeking Alpha]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Hinterhaus Productions/DigitalVision via Getty ImagesAs the field of biopharmaceuticals continues to evolve, one area of significant unmet medical need is the treatment of non-alcoholic steatohepatitis (NASH), a severe form of liver disease that affects millions of individuals worldwide. Akero Therapeutics (NASDAQ:AKRO), a clinical-stage company, has positioned itself as aleading contenderin the race to develop transformative treatments for NASH. With its flagship product, Efruxifermin (EFX), Akero Therapeutics presents a unique and compelling investment opportunity for those seeking exposure to the promising NASH market.Sustainable Balance SheetAs we examine the Q1 2023 financial report of Akero Therapeutics, the company's future appears solidly robust and promising, a clear beacon of optimism for the discerning investor. While some might see an upswing in operating expenses as a red flag, I urge readers to delve deeper into the report's subtle indications of growth andfinancial fort
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROAccesswire
- Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROGlobeNewswire
- Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
AKRO
Earnings
- 11/13/23 - Miss
AKRO
Analyst Actions
- 3/5/24 - UBS
AKRO
Sec Filings
- 4/16/24 - Form PRE
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- AKRO's page on the SEC website